Intraperitoneal therapy of ovarian cancer

During the past decade, intraperitoneal chemotherapy has evolved from a theoretical concept into a rational therapeutic strategy for a select group of individuals with ovarian cancer. Patients who may potentially benefit from this approach include those with small volume intraperitoneal disease at the initiation of initial chemotherapy and individuals with microscopic and very small volume macroscopic cancer after the completion of front-line systemic treatment. Further exploration to define an ultimate role for regional antineoplastic drug delivery in the management of ovarian cancer is warranted.